Overview of Berinert

Quick Facts

Property	Description
Active Ingredient	C1 Esterase Inhibitor (human)
Form	Powder and solvent for solution for injection
Pharmacological Class	Complement Inhibitor
General Purpose	Replacement therapy for acute swelling episodes
Origin	Plasma-derived (from human plasma)

Defining Berinert: Origin, Composition, and Pharmacological Class

Berinert is a highly specialized biological medicine whose active substance is C1 Esterase Inhibitor (human). This therapeutic is classified as a Complement Inhibitor, belonging to the larger group of drugs used in hereditary angioedema (HAE) management (ATC Code: B06AC01). The primary function of the medicine is to provide focused replacement therapy, substituting the C1 Esterase Inhibitor protein that is either missing or malfunctioning in certain patients. As a plasma-derived C1-INH, it serves as a replacement option for correcting the functional deficiency in HAE patients. This specific therapeutic approach is clinically recognized for restoring crucial regulatory protein function during acute episodes.

The composition of Berinert is distinct because its active ingredient, C1 Esterase Inhibitor (C1-INH), is plasma-derived, meaning it is purified and extracted from large pools of donated human plasma. This extensive purification process yields a lyophilized concentrate—a white, freeze-dried powder—which is reconstituted using the supplied Sterile Water for Injection before being administered.

Physical Form and General Therapeutic Intent

The physical form of Berinert is consistently a powder and solvent for solution for injection, provided in single-use vials expressed in International Units (IU), such as 500 IU or 1500 IU. The required route of administration for this medication is intravenous, which ensures the active protein is delivered directly and rapidly into the bloodstream for prompt effect. This IV-based rapid delivery distinguishes it as an on-demand therapy option.

The general therapeutic purpose of Berinert is to act as a crucial regulatory agent, addressing the root cause of acute inflammatory episodes. By replacing the deficient C1-INH activity, the medicine helps to put a "brake" on the internal enzyme cascades, specifically inhibiting the factors that lead to the uncontrolled production of swelling-inducing substances like bradykinin. This stabilizing action serves to halt the progression of acute, localized swelling and limits its severity during an episode, a typical use scenario being the intervention during an acute facial or abdominal attack.

What side effects are possible with Berinert?

Possible Side Effects and Safety Information

The safety profile of Berinert (C1 Esterase Inhibitor) is officially documented by government regulatory bodies, detailing the types and frequency of adverse reactions observed. Adverse events are categorized according to the affected System-Organ-Class and their reported frequency in clinical settings. The regulatory frequency framework classifies reactions into categories such as Common and Uncommon.

Common adverse reactions, officially documented to affect up to 1 in 10 people, include Headache, Nausea, and Rash. Reactions classified as Uncommon, affecting up to 1 in 100 people, include Dizziness, Fever (Pyrexia), Pruritus (Itching), Urticaria (Hives), and local Injection site reactions.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights the potential for Serious Adverse Reactions. These include severe, life-threatening allergic responses such as Anaphylactic Reactions, and the risk of Thromboembolic Events (blood clots). The potential for Thromboembolic Events is a documented warning in the prescribing information.

Due to the medicine's plasma-derived origin (purified from human plasma), a theoretical risk of transmitting infectious agents exists, despite extensive safety procedures and testing. This is a core safety constraint for all plasma-derived products. Furthermore, the safety profile noted for Pediatric patients is generally similar to that of adults, though specific adverse events like Nausea and Headache are commonly observed in this group. The safety structure ensures that the expected clinical safety characteristics and intrinsic risks are formally communicated.

Overdose and Emergency Response

The official regulatory profile for Berinert (C1 Esterase Inhibitor (human)) structures its overdose information around risks associated with exposure beyond recommended levels, as no specific acute overdose syndrome has been formally documented in clinical trials.

Overdose Scope

Property	Official Regulatory Statement
Documented Presentation	Formal reports do not document specific acute overdose symptoms.
Dose-Related Risk	Use at higher than recommended doses or for unapproved indications has been associated with an increased risk of serious thromboembolic (TE) events, affecting the cardiovascular and vascular systems.
Population-Specific Risk	Patients with pre-existing risk factors for thrombosis (e.g., indwelling access devices, prior history of blood clots, morbid obesity) are at heightened risk of TE events, a condition potentially increased by higher doses.

When to Seek Urgent Help

Classification	Label-Derived Phrasing
Mandatory Action	Seek medical attention immediately following self-administration for a laryngeal HAE attack.
Urgent Reporting	Report immediately any signs of a blood clot, such as unexplained shortness of breath, chest pain, or swelling/discoloration of a limb.

Official overdose statements: If a severe adverse reaction or hypersensitivity is suspected, administration must be stopped immediately, and symptomatic and supportive treatment must be initiated. There is no specific antidote for C1 Esterase Inhibitor (human) documented in the regulatory prescribing information.

Therapeutic Uses of Berinert

Berinert is commonly used in clinical settings that involve acute or unstable symptom patterns for adult and pediatric patients to address acute attacks of Hereditary Angioedema (HAE). The medication is relevant for addressing the treatment of acute HAE attacks affecting the abdomen, face, or larynx. This therapeutic domain covers the sudden onset of pronounced swelling, known as nonpitting edema, that creates noticeable physiological strain.

It is relevant in contexts marked by increased discomfort or tension, providing supportive relief in these situations. It assists with managing the escalation of symptoms like debilitating abdominal pain, nausea, vomiting, and most importantly, laryngeal swelling. Applying Berinert helps to ease the overall symptomatic burden and supports patients during difficult episodes by easing distress.

The medication is also considered relevant for short-term preprocedural prophylaxis. This means it may be applied before surgical or major dental procedures known to frequently trigger HAE episodes. This use provides temporary short-term symptomatic assistance and may assist with reducing the potential severity of an HAE attack when a patient is exposed to physiological stress.

Quick Fact: Relief for Acute Swelling
Primary Condition	Hereditary Angioedema (HAE) attacks
Main Symptoms Addressed	Abdominal pain, facial swelling, laryngeal edema
Context of Use	Used when symptoms intensify and supportive relief is needed; short-term symptomatic assistance

Eligibility and Restrictions for Use

Who Can and Cannot Use Berinert?

The population eligibility for Berinert (C1 Esterase Inhibitor) is strictly defined by regulatory authorities based on contraindications and established use in specific patient groups.

Eligibility and Exclusionary Rules

Category	Regulatory Status
Absolute Contraindication	Patients with a known life-threatening severe hypersensitivity reaction (e.g., anaphylaxis) to C1 Esterase Inhibitor or any component of the product must not use Berinert.
Approved Population	Approved for use in both adult and pediatric patients with Hereditary Angioedema (HAE) for the treatment of acute abdominal, facial, or laryngeal attacks.
Prophylaxis (Prevention)	The safety and efficacy of this specific formulation are not established for routine long-term preventive therapy.
Thromboembolic Risk	Use requires careful monitoring in patients with pre-existing risk factors for serious thromboembolic events (blood clots), such as a history of thrombosis or underlying atherosclerosis.

Specific Populations

Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed (i.e., when the potential benefit outweighs the potential risk). It is unknown if the substance is excreted into human milk during lactation.

Older Adults (65 and over): Clinical studies did not include sufficient numbers of subjects aged 65 and over, meaning definitive differential safety and efficacy data for this age group are currently not established.

What should I know about interactions with other medicines?

Official Interaction Profile

The official regulatory interaction profile for C1 Esterase Inhibitor (human) products, including Berinert, is highly focused and defined primarily by two categories: pharmacodynamic risk and administration constraints. No formal drug-drug combinations are explicitly classified as pharmacologically contraindicated in official documents.

Pharmacodynamic Risk Interactions

Co-administration of C1 Esterase Inhibitor products with certain medications is documented as a risk factor for serious arterial and venous thromboembolic (TE) events. This additive risk is specifically cited in the prescribing information for patients also using:

Oral Contraceptives (Estrogen Derivatives)
Certain Androgens

These substance classes are noted for their association with an increased thrombogenic potential, representing a recognized pharmacodynamic interaction pattern.

Procedural and Pharmacokinetic Status

Strict administration constraints constitute a key component of the official interaction profile. The product must not be mixed with any other medicinal products or solutions. Administration requires use of a separate infusion line to prevent product alteration or incompatibility. Regarding metabolic interactions, the Summary of Product Characteristics states that no formal studies assessing interaction with cytochrome P450 (CYP) enzymes or drug transporters have been performed, meaning no pharmacokinetic interactions resulting in altered drug exposure are officially documented.

Mechanism of Action

How Berinert Works

Berinert functions as a targeted protein replacement, supplying active C1-esterase inhibitor (C1-INH) to the blood plasma. This protein is a natural regulator that restores the inhibitory capacity of several enzyme cascades.

Modulating the Contact System

Acting as an inhibitor, C1-INH immediately targets and inactivates key serine proteases, specifically plasma kallikrein and Factor XIIa, thereby decreasing their activity within the Contact System (Kallikrein-Kinin System). This inhibition suppresses the uncontrolled enzymatic cascade.

Limiting Mediator Formation

Suppressing the Contact System halts the downstream breakdown of precursor molecules. This action prevents the formation of the peptide bradykinin, which is responsible for mediating endothelial cell separation. Limiting bradykinin formation is a crucial step in the drug's mechanism.

Physiological Consequence

The resulting reduction in bradykinin signaling maintains the integrity of the endothelial barrier function across blood vessels. This mechanistic consequence limits fluid passage from the bloodstream into surrounding tissues.

Dosage and Administration Information

How Berinert is Used: Administration Guidelines

Berinert is used in a procedure-intensive, on-demand manner, meaning it is administered at the time an acute Hereditary Angioedema (HAE) attack is recognized. The approved method for the treatment of acute abdominal, facial, or laryngeal attacks is strictly by Intravenous (IV) injection. In some regions, a different formulation is also approved for routine prophylaxis (prevention of recurrent attacks) via subcutaneous injection.

Standardized Dosing and Frequency

The core usage instruction for acute episodes is the standardized, weight-based dose of 20 International Units (IU) per kilogram (kg) of body weight. This dosage applies uniformly to both adult and pediatric patients for acute attack treatment. Prescribing information states that doses lower than 20 IU/kg should not be administered. This treatment pattern is characterized by on-demand frequency, with the medicine being administered as a single dose per acute event.

Preparation and Administration Conditions

Berinert is supplied as a lyophilized powder and requires reconstitution before use with the supplied Sterile Water for Injection, USP. Following aseptic preparation, the reconstituted solution must be administered at room temperature and is subject to a strict time constraint: it must be used within eight hours of preparation. Administration must be performed by a slow IV injection at a controlled rate of approximately 4 mL per minute. A critical procedural constraint is the non-mixing rule: the solution must not be combined with any other medicinal products or solutions. Finally, the product labeling permits self-administration by appropriately trained patients or caregivers outside of a medical facility, enabling prompt at-home intervention.

Recent Clinical Evidence

Research evidence / Overview of studies for Berinert

Evidence for Acute HAE Attack Treatment

The medicine was studied in the context of acute swelling attacks of Hereditary Angioedema (HAE) primarily using Randomized Controlled Trials (RCTs) against a placebo. These trials researched patterns of acute abdominal, facial, and laryngeal attacks in adults, adolescents, and pediatric patients (HAE Type I and Type II). Main measurements included the time elapsed to outcomes related to symptom patterns and the duration of symptom activity. Pivotal RCTs generally assessed only a single acute attack, meaning the long-term data relies on later observational studies and registries.

Research into Short-Term Preprocedural Use

Research also examined the scenario of short-term prevention (prophylaxis) before surgical or major dental procedures. Since a dedicated, pivotal RCT is lacking for this purpose, the evidence was observed in retrospective chart reviews and observational settings evaluating daily-life functioning. These studies monitored outcomes related to the incidence of HAE attacks and the rate of rescue medication administration post-procedure.

Long-Term Follow-up, Special Populations, and Uncertainty

The initial observations were in short-term RCTs, but long-term effects are not fully established by that trial design. Long-term, non-interventional patient registries and open-label extension studies contribute context on usage patterns, but this evidence quality varies because observational data is limited by the lack of a control group. Studies included pediatric patients (age 5 and older), but data for infants remain insufficient due to modest sample sizes. Data are still emerging in specific areas due to study structure: follow-up durations were limited for long-term controlled data, and comparative evidence is lacking for some subgroups. Furthermore, the lack of a dedicated RCT for preprocedural prophylaxis means that the evidence for that context is limited.

Key Studies & References

Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2) (RCT Overview)

Frequently Asked Questions (FAQ)

Common questions about Berinert (FAQ)

Q: How quickly can someone expect relief after receiving Berinert?

Studies have examined the time to symptom relief after administration. Official information indicates that for laryngeal (throat) attacks, relief has been reported to start within 15 minutes. For all types of attacks (abdominal, facial, or laryngeal), the majority of patients reported feeling symptom improvement within four hours of receiving the medicine.

Q: What is the typical duration of effect after a dose of Berinert?

The typical duration of the effect is based on the time it takes for symptoms to fully resolve following treatment. In clinical studies, the median time until the complete resolution of Hereditary Angioedema (HAE) symptoms after a dose of the medicine has been reported to be 8.4 hours.

Q: What are the signs of a potential blood clot related to Berinert use?

The official product information includes a warning about the risk of blood clots (thromboembolic events). The official warning regarding the risk of blood clots identifies signs such as pain, swelling, or discoloration of an arm or leg, warmth over the affected area, chest pain, unexplained shortness of breath, or a rapid pulse.

Q: What steps are taken to ensure Berinert's safety from viruses and infectious agents?

Because the medicine is made from human plasma, the manufacturing process includes mandatory steps to manage risk. These steps include screening plasma donors, as well as testing and processes for inactivation or removal of certain viruses and infectious agents.

Q: Can Berinert be used to treat swelling in the throat (laryngeal attacks)?

Yes, Berinert is specifically indicated for the on-demand treatment of acute laryngeal attacks of Hereditary Angioedema (HAE) in both adult and pediatric patients. It is important to note that this specific formulation is not indicated for long-term, routine prevention of HAE attacks.

Q: What should a patient do if they have a history of blood clotting problems before using Berinert?

Official warnings note that in patients with pre-existing risk factors for serious blood clots, such as a history of thrombosis, careful monitoring during and after administration is recommended. This information comes from the official warnings and precautions section.

Q: Can Berinert be used as short-term prophylaxis before a dental procedure?

Research has examined its use for short-term prevention (prophylaxis) before major dental or surgical procedures. However, the official regulatory label for this specific formulation does not establish safety and efficacy for prophylactic therapy, including short-term use.

Q: Why is it important to seek medical attention after self-administering for a laryngeal attack?

Official patient information advises patients who self-administer the medicine for a laryngeal attack to immediately seek medical attention afterwards, reflecting the seriousness of a throat attack. This instruction is explicitly included in the patient counseling section of the prescribing information.

Q: Does Berinert contain sodium, and is this a concern for certain patients?

Yes, Berinert contains sodium chloride and sodium citrate as inactive ingredients, known as excipients. The 500 IU vial contains up to 49 mg of sodium. Official labeling notes that the 1500 IU vial contains less than 1 mmol (23 mg) of sodium.

Q: Is Berinert the same as other C1 esterase inhibitor medicines?

Berinert contains the active protein C1 Esterase Inhibitor (human) derived from plasma. While other medications also provide C1-INH, official documents highlight differences in their manufacturing source (human plasma vs. recombinant), approved uses (acute versus prophylaxis), and approved routes of administration (intravenous versus subcutaneous).

Q: Can Berinert be used by children, and is the effect different in them?

The medicine is approved for use in both adults and pediatric patients aged 5 years and older. In clinical trials, the half-life was observed to be shorter and clearance faster in children compared to adults; the clinical significance of this difference is not fully known.

Q: Is it possible to have an HAE attack that does not respond to Berinert?

Clinical trials indicate that the vast majority of treated attacks required only one dose of Berinert. However, official data shows that a small percentage of attacks did require a second dose of the medicine within 24 hours of the first dose.

Q: What is 'dysgeusia' and why is it a common reported side effect?

Dysgeusia is a term for a bad or altered taste in the mouth. Official adverse reaction data indicates that this was the most common adverse reaction reported more frequently in patients receiving Berinert than in those receiving a placebo during clinical studies.

Q: Can Berinert interact with any common over-the-counter medications?

Formal clinical studies to evaluate drug interactions with all non-prescription or common over-the-counter medicines have not been performed. Official labeling primarily focuses on identifying the increased risk of blood clots when Berinert is co-administered with certain hormone-containing products, like oral contraceptives or androgens.

Q: What is the difference between Berinert's IV and SC formulations, if both exist?

The formulation administered intravenously (IV) is approved for the on-demand treatment of acute HAE attacks. A separate formulation, administered subcutaneously (SC), is approved in some countries for the routine, preventative treatment (prophylaxis) of recurrent HAE attacks.

Q: Is Berinert approved for any other uses besides acute HAE attacks?

Berinert is indicated only for the treatment of acute abdominal, facial, or laryngeal attacks of Hereditary Angioedema (HAE). The safety and efficacy for long-term preventive therapy have not been established under the current approval for this specific formulation, and it is indicated only for acute HAE attacks.

Q: Is Berinert used to treat other types of angioedema besides hereditary angioedema?

Berinert is indicated specifically for the treatment of attacks related to Hereditary Angioedema (HAE). There is no official regulatory indication for its use in treating other forms of angioedema, such as acquired angioedema or drug-induced swelling.

Q: What are the official clinical trials that supported Berinert's approval?

Official approval was primarily supported by data from a key placebo-controlled clinical trial, which studied the time it took for HAE symptoms to be relieved. This trial is known as the International, Multicenter, Placebo-controlled, Acute C1-Inhibitor Trial (IMPACT).

Q: Does Berinert work by reducing bradykinin production?

The medicine is a replacement therapy that supplies the C1-INH protein. By doing this, it helps regulate the Contact System, which ultimately reduces the uncontrolled enzyme activity that leads to the formation of the swelling-causing substance, bradykinin.

Q: Can HAE attacks be triggered by stress, illness, or medical procedures?

Official information describing Hereditary Angioedema (HAE) often notes that attacks can occur randomly. They may also be triggered by certain factors, including psychological stress, infections or illness, minor trauma, or surgical and dental procedures.

How should Berinert be stored and disposed of?

Storage and Disposal Requirements for Berinert

The official requirements for storing Berinert (C1 Esterase Inhibitor, Human) address conditions for the unopened product and the solution after reconstitution.

Storage Conditions

Product Form	Temperature Constraint	Protection Requirement
Unopened Vial (Powder)	Store up to 30°C (86°F); Do not freeze	Keep in the original outer carton to protect from light.
Reconstituted Solution	Store up to 30°C; Do not refrigerate or freeze	Use promptly; must be used within 8 hours of reconstitution.

All vials must be kept out of the sight and reach of children. The product is provided as a single-use vial and contains no preservative.

Disposal Instructions

Any unused reconstituted solution and all waste material must be discarded immediately after use. Disposal of this medicine must be carried out in accordance with local requirements. The official label advises against disposing of the medicine via wastewater or household waste.

Berinert